Kunal Parekh, MD
Nephrology · Honolulu, HINPI 1205141793
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $152,744 of the $171,776 with a category attached, or 88.9%. Bayer accounts for 71.4% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $51,771, more than ten times the $453 reported in 2019. Among nephrology clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 448 payments — averaging $383.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$123K
- GSK$25K
- Travere Therapeutics, Inc.$16K
- Calliditas Therapeutics US Inc.$2K
- Amarin Pharma, Inc.$1K
- AstraZeneca$1K
- plus $4K from 18 others
What the payments were for
- Consulting fees$4,1002%
- Speaking & faculty fees$152,74489%
- Travel & lodging$1,8271%
- Food & beverage$12,8297%
- Education$2770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 153 | $122,655 |
| GSK | 42 | $24,975 |
| Travere Therapeutics, Inc. | 29 | $16,444 |
| Calliditas Therapeutics US Inc. | 10 | $1,887 |
| Amarin Pharma, Inc. | 36 | $1,067 |
| AstraZeneca | 40 | $1,057 |
| Amgen(2 entities) | 47 | $954 |
| Novartis | 31 | $571 |
| Novo Nordisk | 19 | $532 |
| Nxstage Medical, Inc. | 7 | $341 |
| Baxter Healthcare | 4 | $319 |
| Ardelyx, Inc. | 9 | $288 |
| Mallinckrodt Hospital Products Inc. | 5 | $220 |
| Outset Medical Inc | 1 | $140 |
| Vifor Pharma, Inc. | 3 | $68 |
| Akebia Therapeutics Inc | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Kyowa Kirin, Inc. | 1 | $33 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| Cormedix Inc. | 1 | $23 |
| Amicus Therapeutics, Inc. | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Fresenius USA Marketing, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$120,995
- BENLYSTA$24,347
- Filspari$5,854
- TARPEYO$1,727
- LOKELMA$255
- Renal - Acute$247
- XPHOZAH 30 MG$124
- Tavneos$124
- RYBELSUS$122
- NXSTAGE SYSTEM ONE$109
How this compares
$171,776 in reported general payments places this provider in the 95th percentile of 57 nephrology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 35 | $126,685 |
| KerendiaFinerenone | 80 | $121,124 |
| JardianceEmpagliflozin | 42 | $58,803 |
| VeltassaPatiromer Calcium Sorbitex | 26 | $57,259 |
| FarxigaDapagliflozin Propanediol | 40 | $52,375 |
| EntrestoSacubitril/Valsartan | 22 | $41,016 |
| RybelsusSemaglutide | 13 | $25,925 |
| Sevelamer Carbonate | 51 | $16,153 |
| VascepaIcosapent Ethyl | 14 | $13,613 |
| AranespDarbepoetin Alfa In Polysorbat | 21 | $6,774 |
| Calcium Acetate | 31 | $2,935 |
| Torsemide | 44 | $2,331 |
| SpsSodium Polystyrene Sulfon/Sorb | 11 | $1,446 |
| Atorvastatin Calcium | 47 | $1,438 |
| Losartan Potassium | 70 | $1,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $122,655 | $121,12480 claims |
| AstraZenecaFarxiga | $1,057 | $52,37540 claims |
| NovartisEntresto | $571 | $41,01622 claims |
| Novo NordiskRybelsus | $532 | $25,92513 claims |
| AmgenAranesp | $954 | $6,77421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 nephrology providers in Hawaii.
Other nephrology in Honolulu
- Christie IzutsuHonolulu$50K
- Jared SugiharaHonolulu$39K
- Eugene WongHonolulu$37K
- Shiuh ChengHonolulu$21K
- Leilani Ka'aneheHonolulu$10K
- Antonette Veronica HernandezHonolulu$9K
- Rick HayashiHonolulu$5K
- David NaaiHonolulu$5K
- Arie Olivo GanzHonolulu$5K
- Sorkko ThirunavukkarasuHonolulu$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.